Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
Chronic migraine is a disabling neurovascular disorder that ranks amongst the top causes of years lived with disability worldwide. The duration and the frequency of migraine affect cognitive and affective domains, inducing worsening of memory, executive functions, orientation and causing anxiety. Po...
Saved in:
Main Authors: | M. T. Corasaniti (Author), G. W. Lawrence (Author), G. Bagetta (Author), R. Iannacchero (Author), A. Tarsitano (Author), A. Monteleone (Author), M. Pagliaro (Author), P. Tonin (Author), G. Sandrini (Author), P. Nicotera (Author), D. Scuteri (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023) -
Effect of Xiongmatang Extract on Behavioral and TRPV1-CGRP/CGRP-R Pathway in Rats With Migraine
by: Dingding Liu, et al.
Published: (2022) -
Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
by: Aqfan Jamaluddin, et al.
Published: (2022) -
Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023)